Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: A meta-analysis and systematic review

Osteoporosis International

Volumn 21, Issue 1, 2010, Pages 183-187

  Mamtani, M ^a   Kulkarni, H ^b  

^a Lata Medical Research Foundation   (India)

^b NONE   (United States)

Author keywords

Osteoclasts; Thalassemia; Zoledronate

Indexed keywords

ZOLEDRONIC ACID;

BONE DENSITY; BONE PAIN; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMUR NECK; HUMAN; LUMBAR SPINE; META ANALYSIS; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THALASSEMIA; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 72449149285     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0875-4     Document Type: Review

References (37)

1. NA Johanson 1990 Musculoskeletal problems in hemoglobinopathy Orthop Clin North Am 21 191 198 1:STN:280:DyaK3c7hsV2ntA%3D%3D 2296457
2. J Michelson A Cohen 1988 Incidence and treatment of fractures in thalassemia J Orthop Trauma 2 29 32 10.1097/00005131-198802000-00007 1:STN:280:DyaL1M7ktFajtw%3D%3D 3225698
3. P Pootrakul S Hungsprenges S Fucharoen D Baylink E Thompson E English M Lee J Burnell C Finch 1981 Relation between erythropoiesis and bone metabolism in thalassemia N Engl J Med 304 1470 1473 1:STN:280:DyaL3M7pslGhuw%3D%3D 7231478
4. E Voskaridou E Stoupa L Antoniadou E Premetis K Konstantopoulos I Papassotiriou E Terpos 2006 Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis Haematologica 91 813 816 1:CAS:528:DC%2BD28XntF2jtLo%3D 16704959
5. CE Jensen SM Tuck JE Agnew S Koneru RW Morris A Yardumian E Prescott AV Hoffbrand B Wonke 1998 High incidence of osteoporosis in thalassaemia major J Pediatr Endocrinol Metab 11 Suppl 3 975 977 10091176
6. CE Jensen SM Tuck JE Agnew S Koneru RW Morris A Yardumian E Prescott AV Hoffbrand B Wonke 1998 High prevalence of low bone mass in thalassaemia major Br J Haematol 103 911 915 10.1046/j.1365-2141.1998.01108.x 1:STN:280: DyaK1M7gtFeqsw%3D%3D 9886300 (Pubitemid 29012624)
7. AA Shamshirsaz MR Bekheirnia M Kamgar N Pourzahedgilani N Bouzari M Habibzadeh R Hashemi AA Shamshirsaz S Aghakhani H Homayoun B Larijani 2003 Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran BMC Endocr Disord 3 4 10.1186/1472-6823-3-4 12914670 (Pubitemid 38671504)
8. O Gurevitch S Slavin 2006 The hematological etiology of osteoporosis Med Hypotheses 67 729 735 10.1016/j.mehy.2006.03.051 16797864 (Pubitemid 44062149)
9. HA Fleisch 1997 Bisphosphonates: preclinical aspects and use in osteoporosis Ann Med 29 55 62 10.3109/07853899708998743 1:CAS:528: DyaK2sXjtleks7s%3D 9073324
10. A Gaudio N Morabito A Xourafa I Macri A Meo S Morgante A Trifiletti A Lasco N Frisina 2008 Bisphosphonates in the treatment of thalassemia-associated osteoporosis J Endocrinol Invest 31 181 184 1:CAS:528:DC%2BD1cXmt1emsbY%3D 18362512
11. P Mahachoklertwattana 2006 Zoledronic acid for the treatment of thalassemia-induced osteonecrosis Haematologica 91 1155A 16956807
12. CP Gilfillan BJ Strauss CP Rodda DK Bowden AM Kean M Obaid BA Crawford 2006 A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia Calcif Tissue Int 79 138 144 10.1007/s00223-006-0314-x 1:CAS:528:DC%2BD28XpvFalsLw%3D 16969592 (Pubitemid 44440441)
13. N Morabito A Lasco A Gaudio A Crisafulli C Di Pietro A Meo N Frisina 2002 Bisphosphonates in the treatment of thalassemia-induced osteoporosis Osteoporos Int 13 644 649 10.1007/s001980200087 1:CAS:528:DC%2BD38Xns1entb4%3D 12181623 (Pubitemid 34885856)
14. ZK Otrock ST Azar WA Shamseddeen D Habr A Inati S Koussa RA Mahfouz AT Taher 2006 Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial Ann Hematol 85 605 609 10.1007/s00277-006-0136-y 1:CAS:528:DC%2BD28XosFWktbY%3D 16830143 (Pubitemid 44283081)
15. ZK Otrock RA Mahfouz KM Charafeddine RF Rayes LF Zahed AT Taher 2008 Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis Ann Hematol 87 947 948 10.1007/s00277-008-0497- 5 18443790
16. P Pennisi G Pizzarelli M Spina S Riccobene CE Fiore 2003 Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis J Bone Miner Metab 21 402 408 10.1007/s00774-003-0435-5 14586797 (Pubitemid 38017697)
17. V Perifanis T Vyzantiadis K Tziomalos S Vakalopoulou V Garipidou M Athanassiou-Metaxa F Harsoulis 2007 Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia Ann Hematol 86 23 30 10.1007/s00277-006-0180-7 1:CAS:528:DC%2BD28Xht1ynu7%2FI 17013645 (Pubitemid 46138314)
18. V Perifanis T Vyzantiadis S Vakalopoulou K Tziomalos V Garypidou M Athanassiou-Metaxa F Harsoulis 2004 Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid Br J Haematol 125 91 92 10.1111/j.1365-2141. 2004.04871.x 15015977 author reply 93-4 (Pubitemid 38453285)
19. E Voskaridou A Anagnostopoulos K Konstantopoulos E Stoupa E Spyropoulou C Kiamouris E Terpos 2006 Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial Haematologica 91 1193 1202 1:CAS:528: DC%2BD28XhtVOhtL%2FJ 16956818
20. E Voskaridou D Christoulas L Antoniadou E Terpos 2008 Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis Acta Haematol 119 40 44 10.1159/000114869 18253025
21. E Voskaridou D Christoulas M Konstantinidou E Tsiftsakis P Alexakos E Terpos 2008 Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial Haematologica 93 1588 1590 10.3324/haematol.12849 1:CAS:528:DC%2BD1cXhtl2gurrM 18698086
22. E Voskaridou E Terpos G Spina J Palermos A Rahemtulla A Loutradi D Loukopoulos 2003 Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia Br J Haematol 123 730 737 10.1046/j.1365-2141. 2003.04657.x 1:CAS:528:DC%2BD3sXpvF2iu7c%3D 14616979 (Pubitemid 37468072)
23. B Wonke C Jensen JJ Hanslip E Prescott M Lalloz M Layton S Erten S Tuck JE Agnew K Raja K Davies AV Hoffbrand 1998 Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major J Pediatr Endocrinol Metab 11 Suppl 3 795 801 10091149
24. USFDA (2008) Information for Healthcare Professionals. http://www.fda.gov/cder/drug/InfoSheets/HCP/bisphosphonatesHCP.htm
25. USFDA (2008) Early Communication of an Ongoing Safety Review. http://www.fda.gov/cder/drug/early-comm/bisphosphonates.htm
26. DM Black PD Delmas R Eastell IR Reid S Boonen, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D 17476007 (Pubitemid 46698462)
27. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid in reducing clinical fracture and mortality after hip fracture N Engl J Med 357 1799 1809 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN 17878149 nihpa40967 (Pubitemid 350044800)
28. C Borgna-Pignatti MD Cappellini P De Stefano GC Del Vecchio GL Forni MR Gamberini R Ghilardi R Origa A Piga MA Romeo H Zhao A Cnaan 2005 Survival and complications in thalassemia Ann N Y Acad Sci 1054 40 47 10.1196/annals.1345.006 1:STN:280:DC%2BD2MnlsFCnsQ%3D%3D 16339650 (Pubitemid 43031009)
29. M Toumba A Sergis C Kanaris N Skordis 2007 Endocrine complications in patients with Thalassaemia Major Pediatr Endocrinol Rev 5 642 648 18084158
30. G Derchi P Bellone GL Forni G Lupi S Jappelli M Randazzo V Zino C Vecchio 1992 Cardiac involvement in thalassaemia major: altered atrial natriuretic peptide levels in asymptomatic patients Eur Heart J 13 1368 1372 1:STN:280:DyaK3s%2FhtFaksg%3D%3D 1396810
31. M Mamtani H Kulkarni 2008 Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis Br J Haematol 141 882 890 10.1111/j.1365-2141.2008.07122.x 1:CAS:528:DC%2BD1cXotlCqs7g%3D 18355381 (Pubitemid 351724860)
32. Patane S, Marte F (2008) Abnormal troponin I levels in a thalassemia major patient with high ferritin concentration, permanent atrial fibrillation and without acute coronary syndrome. Int J Cardiol doi: 10.1016/j.ijcard.2008. 06.039
33. NG Angelopoulos A Goula E Katounda G Rombopoulos V Kaltzidou D Kaltsas E Konstandelou G Tolis 2007 Markers of bone metabolism in eugonadal female patients with beta-thalassemia major Pediatr Hematol Oncol 24 481 491 10.1080/08880010701533611 1:CAS:528:DC%2BD2sXhtVSksL%2FN 17786784 (Pubitemid 47360016)
34. NG Angelopoulos A Goula E Katounda G Rombopoulos V Kaltzidou D Kaltsas S Malaktari V Athanasiou G Tolis 2007 Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major J Bone Miner Metab 25 60 67 10.1007/s00774-006-0728-6 1:CAS:528:DC%2BD28XhtlGitbbL 17187195 (Pubitemid 46012998)
35. E Voskaridou E Terpos 2004 New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia Br J Haematol 127 127 139 10.1111/j.1365-2141.2004.05143.x 1:CAS:528:DC%2BD2cXpvFait70%3D 15461618 (Pubitemid 39371805)
36. JE Brown SP Ellis JE Lester S Gutcher T Khanna OP Purohit E McCloskey RE Coleman 2007 Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid Clin Cancer Res 13 5406 5410 10.1158/1078-0432.CCR-07-0247 1:CAS:528:DC%2BD2sXhtVCitLzI 17875770 (Pubitemid 47510367)
37. JY Reginster O Malaise A Neuprez VE Jouret P Close 2007 Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date Drugs Aging 24 351 359 10.2165/00002512-200724050-00001 1:CAS:528:DC%2BD2sXot1Gjsbg%3D 17503893 (Pubitemid 46790260)